文献速递妇科

可能致癌HPV亚型可致HSIL且临床HPV检测阴性

Possibly carcinogenic HPV subtypes are a cause of HSIL and negative clinical HPV tests - A European prospective single center study.
PubMed 文献 · Gynecol Oncol · 2020-04-27

该欧洲单中心前瞻性研究对388例宫颈癌前病变患者进行p16ink4a与临床HPV-DNA及E6/E7 mRNA检测相关性分析。374例为HSIL,14例为AIS。Aptima漏检10/388(2.6%),Cobas漏检7/388(1.8%),双阴性20/374(5.3%)。双阴性HSIL中50%与可能致癌及低危HPV相关,均为两种检测未覆盖亚型。结论认为临床HPV检测未覆盖的可能致癌亚型可解释部分漏检HSIL,真HPV阴性HSIL极罕见。

要点

  • Aptima漏检2.6%、Cobas漏检1.8%的HPV相关癌前病变。
  • 双阴性癌前病变占5.3%,其中HSIL以CIN3为主。
  • 双阴性HSIL中50%与HPV73、53等检测未覆盖亚型相关。

核心结论

  • 临床HPV检测未覆盖的可能致癌HPV亚型可解释临床HPV筛查中漏检HSIL的一小部分缺口。
  • 真HPV阴性HSIL极为罕见。
  • 扩大HPV检测覆盖更多可能致癌亚型可能进一步减少宫颈癌。

研究设计与样本

  • 欧洲单中心前瞻性研究,连续纳入388例患者。
  • 374/388例为HSIL(CIN 2/3),14/388例为AIS(6例单纯AIS,8例AIS合并HSIL)。
  • 对临床Cobas和/或Aptima HPV检测阴性的HSIL/AIS病变组织行CHIPRON HPV 3.5 LCD-array基因分型,部分病例行癌症热点分析。

主要发现

  • Aptima检测漏检10/388(2.6%)HPV-HR相关癌前病变,Cobas检测漏检7/388(1.8%)。
  • 两种HPV检测均阴性者20/374(5.3%),其中17例HSIL/CIN3、2例HSIL/CIN2、1例AIS。
  • 20例双阴性病例中4例(3例HSIL、1例AIS)因DNA不足未行基因分型。
  • 可基因分型的双阴性HSIL中,2/20(10%)检出HR-HPV亚型。
  • 10/20(50%)HSIL与可能致癌及低危HPV相关:4例HPV73、3例HPV53、1例HPV82、1例HPV67、1例HPV6,均未被两种HPV检测覆盖。

临床怎么用

  • 临床解读双阴性HPV结果时需考虑检测未覆盖的可能致癌亚型。
  • 对细胞学或组织学异常而HPV阴性的HSIL病例应谨慎评估。
  • 未来HPV检测扩展亚型覆盖可能提高筛查敏感性。

局限性

  • 单中心研究,样本量有限。
  • 4例双阴性病例因DNA不足未行基因分型。
  • 部分病例仅行癌症热点分析,未全面评估其他分子机制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To correlate p16ink4a positive cervical precancers of 388 consecutive patients from a single European center with the preceding clinical HPV-DNA and HPV E6/E7 mRNA screening test. METHOD: 374/388 patients had a HSIL (CIN 2/3) and 14/388 AIS (6 pure and 8 combined AIS/HSIL). Lesional tissues of HSIL/AIS with negative Cobas and/or Aptima HPV tests underwent HPV genotyping with CHIPRON HPV 3.5 LCD-array. Selected cases were subjected to a cancer hot spot analysis. RESULTS: The Aptima test missed 10/388 (2.6%) and the Cobas test seven of 388 (1.8%) precancers associated HPV-HR. Both HPV tests were negative in 20/374 precancers (5.3%; 17 HSIL/CIN3, two HSIL/CIN2, one AIS). Due to insufficient DNA four of 20 double negative cases (three HSIL, one AIS) were not genotyped. In the remaining cases, two of 20 (10%) HSIL genotyping detected HR-HPV subtypes. 10/20 (50%) HSIL were associated with possibly carcinogenic and low risk HPV (four x HPV73, three x HPV 53, one x HPV 82, one x HPV 67 and one x HPV 6), all of which are not included in both HPV tests. Two of 20 (10%) HSIL were negative with all HPV tests; one of these HSIL had a somatic PIK3CA gene mutation and the other had a single nucleotide variant in the APC gene. Three of 20 HSIL (15%) were thin HSIL (≤9 cell layers thick). CONCLUSIONS: Possibly carcinogenic HPV subtypes not included in the clinical HPV tests may account for the small gap of missed HSIL in clinical HPV screening. True HPV negative HSIL are exceedingly rare. Expanding HPV testing to include more possibly carcinogenic HPV subtypes may further reduce cervical cancer.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Reich O, Regauer S, Kashofer K, et al. Possibly carcinogenic HPV subtypes are a cause of HSIL and negative clinical HPV tests - A European prospective single center study. Gynecol Oncol. 2020. PMID: 32354471. doi:10.1016/j.ygyno.2020.04.685

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。